What Is Passage Bio, Inc. (PASG) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Passage Bio, Inc. presents a highly debated valuation profile at its current price of $4.46. The composite intrinsic value is estimated at $8.78 (+96.8% average upside), masking a wide model spread between the 3 bullish models and 3 bearish models. Model dispersion is worth noting: ML-RIV targets $22.04 (+394.2%), versus Sentiment SOTP at $3.07 (-31.1%). This +425.3% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About PASG?
6 of 13 models are currently active for PASG. Of these, 3 models suggest upside while 3 models suggest overvaluation. The Bayesian DCF estimates PASG's intrinsic value at $3.44, implying -23.0% downside from the current price. See which stocks rank higher →
How Does PASG Rank in Biological Products, (No Diagnostic Substances)?
Among 139 Biological Products, (No Diagnostic Substances) stocks, PASG ranks #123 by Quality of Company score. CirclFi's QOC score of 3.9/10 evaluates 32 fundamental signals. A score of 3.9 signals below-average fundamentals.
See all Most Undervalued Biological Products, (No Diagnostic Substances) Stocks →
Passage Bio, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.
Is PASG a Value Trap?
CirclFi's Value Trap algorithm assigns PASG a score of 24/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
6 of 13 models are active for Passage Bio, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Passage Bio, Inc. is rated at 3.9/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.
The gap between the most bullish and bearish model spans +425.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every PASG valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across PASG's 6 active models, average confidence is 22%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad